iconEarnings Announcement After Market Close

NRX Pharmaceuticals Inc NRXP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:41 PM EDT
3.24quote price arrow up+0.25 (+8.34%)
Volume
230,947
52 week range
1.90 - 12.00
Loading...
  • Open3.01
  • Day High3.29
  • Day Low2.93
  • Prev Close2.99
  • 52 Week High12.00
  • 52 Week High Date06/02/23
  • 52 Week Low1.90
  • 52 Week Low Date05/02/24

Key Stats

  • Market Cap34.193M
  • Shares Out10.56M
  • 10 Day Average Volume1.40M
  • Dividend-
  • Dividend Yield-
  • Beta1.22
  • YTD % Change-29.35

KEY STATS

  • Open3.01
  • Day High3.29
  • Day Low2.93
  • Prev Close2.99
  • 52 Week High12.00
  • 52 Week High Date06/02/23
  • 52 Week Low1.90
  • 52 Week Low Date05/02/24
  • Market Cap34.193M
  • Shares Out10.56M
  • 10 Day Average Volume1.40M
  • Dividend-
  • Dividend Yield-
  • Beta1.22
  • YTD % Change-29.35

RATIOS/PROFITABILITY

  • EPS (TTM)-3.62
  • P/E (TTM)-0.89
  • Fwd P/E (NTM)-2.42
  • EBITDA (TTM)-27.582M
  • ROE (TTM)-682.81%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-78.08%

EVENTS

  • Earnings Date05/14/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On NRX Pharmaceuticals Inc

 

Profile

MORE
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The...
Stephen Willard
Chief Executive Officer, Director
Richard Narido
Interim Chief Financial Officer
Address
1201 ORANGE STREET, SUITE 600
Wilmington, DE
19801
United States